StockData
Champions Oncology, Inc. logo

Champions Oncology, Inc. (CSBR) stock

CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30227% above fair value
$4.44−0.15 (-3.30%)

Close on Nov 18, 2026Market cap $61.80MP/E –Yield –

Champions Oncology free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Champions Oncology's free cash flow for the twelve months ending Jul 31, 2026 was -$6.14M, down 184.8% year over year. For fiscal 2026 it was -$5.04M, down 172.0% from the year before. The highest annual figure on record is $7.00M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2026Apr 30, 2026-$5.04M-172.0%
FY2025Apr 30, 2025$7.00M–
FY2024Apr 30, 2024-$6.97M-733.9%
FY2023Apr 30, 2023$1.10M-73.3%
FY2022Apr 30, 2022$4.11M–
FY2021Apr 30, 2021-$4.96M-824.4%
FY2020Apr 30, 2020$685.00K-33.4%
FY2019Apr 30, 2019$1.03M–
FY2018Apr 30, 2018-$2.46M–
FY2017Apr 30, 2017-$3.61M–
FY2016Apr 30, 2016-$6.73M–
FY2015Apr 30, 2015-$9.75M–
FY2014Apr 30, 2014-$3.67M–
FY2013Apr 30, 2013-$4.36M–
FY2012Apr 30, 2012-$5.75M–
FY2011Apr 30, 2011-$139.00K–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jul 31, 2026-$547.00K-198.7%
Q4 FY2026CQ1 2026Apr 30, 2026-$2.24M-133.8%
Q3 FY2026CQ4 2025Jan 31, 2026-$1.38M-407.1%
Q2 FY2026CQ3 2025Oct 31, 2025-$1.98M–
Q1 FY2026CQ2 2025Jul 31, 2025$554.00K+78.1%
Q4 FY2025CQ1 2025Apr 30, 2025$6.62M–
Q3 FY2025CQ4 2024Jan 31, 2025$448.00K–
Q2 FY2025CQ3 2024Oct 31, 2024-$377.00K-173.9%
Q1 FY2025CQ2 2024Jul 31, 2024$311.00K–
Q4 FY2024CQ1 2024Apr 30, 2024-$1.81M–
Q3 FY2024CQ4 2023Jan 31, 2024-$1.01M-223.4%
Q2 FY2024CQ3 2023Oct 31, 2023$510.00K-81.0%
Q1 FY2024CQ2 2023Jul 31, 2023-$4.66M–
Q4 FY2023CQ1 2023Apr 30, 2023-$1.45M-600.7%
Q3 FY2023CQ4 2022Jan 31, 2023$819.00K-78.7%
Q2 FY2023CQ3 2022Oct 31, 2022$2.68M+305.1%
Q1 FY2023CQ2 2022Jul 31, 2022-$949.00K–
Q4 FY2022CQ1 2022Apr 30, 2022$290.00K–
Q3 FY2022CQ4 2021Jan 31, 2022$3.85M–
Q2 FY2022CQ3 2021Oct 31, 2021$662.00K+77.5%
Q1 FY2022CQ2 2021Jul 31, 2021-$691.00K–
Q4 FY2021CQ1 2021Apr 30, 2021-$2.83M-378.4%
Q3 FY2021CQ4 2020Jan 31, 2021-$1.07M-1088.9%
Q2 FY2021CQ3 2020Oct 31, 2020$373.00K-36.5%
Q1 FY2021CQ2 2020Jul 31, 2020-$1.43M–
Q4 FY2020CQ1 2020Apr 30, 2020$1.02M+817.1%
Q3 FY2020CQ4 2019Jan 31, 2020$108.00K-89.2%
Q2 FY2020CQ3 2019Oct 31, 2019$587.00K–
Q1 FY2020CQ2 2019Jul 31, 2019-$1.03M-922.4%
Q4 FY2019CQ1 2019Apr 30, 2019$111.00K–
Q3 FY2019CQ4 2018Jan 31, 2019$1.00M+171.1%
Q2 FY2019CQ3 2018Oct 31, 2018-$211.00K-189.4%
Q1 FY2019CQ2 2018Jul 31, 2018$125.00K–
Q4 FY2018CQ1 2018Apr 30, 2018-$203.00K–
Q3 FY2018CQ4 2017Jan 31, 2018$370.00K–
Q2 FY2018CQ3 2017Oct 31, 2017$236.00K+129.1%
Q1 FY2018CQ2 2017Jul 31, 2017-$2.86M–
Q4 FY2017CQ1 2017Apr 30, 2017-$187.00K–
Q3 FY2017CQ4 2016Jan 31, 2017-$835.00K–
Q2 FY2017CQ3 2016Oct 31, 2016$103.00K–

More Champions Oncology figures

See a number that looks wrong?